473548-05-9

Upstream product

• 473537-92-7 ethyl 4-(3-bromophenyl)-2,4-dioxobutanoate 
• 60-34-4 methylhydrazine 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 64-17-5 ethanol 
• 93618-22-5 methyl 4-(3-bromophenyl)-2,4-dioxobutanoate 
• 21575-91-7 ethyl 3-bromobenzoylacetate 

Downstream Products

• 1107658-91-2 5-(3-benzofuran-2-yl-phenyl)-1-methyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 1107658-92-3 5-(3-benzofuran-2-yl-phenyl)-1-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 852816-28-5 5-(3-bromo-phenyl)-1-methyl-1H-pyrazole-3-carboxylic acid 
• 1107658-90-1 5-(3-benzofuran-2-yl-phenyl)-1-methyl-1H-pyrazole-3-carboxylic acid 
• 1616930-44-9 C₁₆H₁₅N₃O₂S 
• 1616929-89-5 N-(2,6-difluoro-phenyl)-1-methyl-5-(3-thiazol-2-yl-phenyl)-1H-pyrazole-3-carboxylic acid amide 
• 473548-03-7 (RS)-3-{3-[2-methyl-5-(tetrahydro-pyran-2-yloxymethyl)-2H-pyrazol-3-yl]-phenyl}-3-oxo-propionic acid tert.-butyl ester 

Relevant academic research and scientific papers

Pyrazolyl-Based Carboxamides I

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

PYRAZOLYL-BASED CARBOXAMIDES I AS CRAC CHANNEL INHIBITORS

The Invention relates to pyrazolyl-based carboxamide compounds of formula (l) useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

PYRAZOL DERIVATIVES

The invention is concerned with novel pyrazol derivatives of formula (I), wherein R1, R2, R3, R4, X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.

SUBSTITUTED PYRAZOLES AS PPAR AGONISTS

A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof (I) wherein: p is O or 1; q is O or 1; R1 and R2 are independently H or C1-3 alkyl; R3 and R4 are independently H, C1-6 alkyl, -OC1-6 alkyl, halogen, OH, C2-6 alkenyl or CF3; R5 is H, C1-6 alkyl (optionally substituted by one or more halogens, -COphenyl, OC1-6 alkyl, phenyl morpholino or C2-6 alkenyl. R6 is C1-6 alkyl, halogen, -OCH2 phenyl, phenyl (optionally substituted by C1-3 alkiyl), morpholino, pyrrolidino, piperidino, thiophenyl, furanyl pyridinyl or -OC2-6 alkenyl. These compounds activate the alpha and gamma subtypes fo the hppar receptor and are useful e.g. in the treatment of diabetes, dyslipidemia or syndrome X.

BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS

Biaryl substituted pyrazole compounds are sodium channel blockers useful for the treatment of pain and other conditions. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more th